Healthcare and defensives led a split tape while technology weakness centered on semiconductors and AI-sensitive growth.

• Index split: S&P 500 -1.95%, NASDAQ 100 -4.24%, Dow +0.60%.
• Defensive and rate-sensitive leadership came from XLV, XLU, and XLRE.
• The main pressure point was XLK, reinforced by weakness in semiconductors and AI-linked growth.
• Macro stress gauges stayed relatively orderly even as equity leadership narrowed.

The past week showed a clear defensive rotation beneath the headline index mix. The S&P 500 fell 1.95% and the NASDAQ 100 dropped 4.24%, while the Dow Jones still gained 0.60%, signaling that weakness was concentrated in growth and technology rather than spread evenly across the market.

Leadership came from Healthcare at +7.32%, Utilities at +3.22%, and Real Estate at +3.15%. The weakest areas were Tech at -5.40%, alongside sharp declines in Bitcoin and Silver. With VIX at 18.41, the yield curve still positive at 0.31, and high-yield spreads contained at 2.78, the week looked more like a positioning reset than a broad credit-driven risk event.

• Healthcare strength had a concrete catalyst in new clinical data rather than only defensive rotation.
• AI policy news remained constructive, but it did not prevent broader de-risking in growth-heavy technology.
• Contained credit spreads and a moderate VIX argue against a systemic risk read-through.
• The cautious stance that has been in place since June 24 still fits a market rewarding selectivity over broad beta.

The strongest fundamental support in the week’s leadership came from healthcare, especially biotech and large-cap drug exposure. New Johnson & Johnson data on nipocalimab highlighted sustained disease control in generalized myasthenia gravis from the Phase 3 Vivacity-MG3 study, adding to the sense that investors were rewarding companies with clinically tangible catalysts and more idiosyncratic earnings paths than the broader tech complex.

On the weak side, technology’s drawdown appeared tied to a reassessment of high-beta AI and semiconductor exposure rather than a complete collapse in innovation news. Reporting showed Anthropic’s Mythos 5 model received U.S. clearance for wider use among certain trusted partners, which underscored that AI development continues, but the equity tape still favored defensives over the most crowded AI-linked trades. That divergence helps explain why cloud and cybersecurity held up better than semiconductors and robotics.

• Biotech was the standout winner, with pipeline and clinical-data stories helping power XBI’s outperformance.
• Cybersecurity and cloud held up better than the broader tech complex, suggesting selective preference for software and resilient digital-spend themes.
• Semiconductors and robotics/AI were the main growth casualties, pointing to crowding and valuation pressure inside hardware-heavy AI trades.
• Clean energy and solar remained weak, while space was one of the sharpest refined-theme laggards, reinforcing the market’s lower tolerance for speculative capital-intensive stories.

The clearest winning micro-theme was biotech. XBI surged 10.42%, far ahead of the S&P 500, and the fresh healthcare news flow pointed to disease-specific pipeline progress as a driver of risk appetite within an otherwise defensive sector. That is an important distinction: investors were not only hiding in staples-like healthcare cash flows, they were also paying for clinical upside where the catalyst was visible.

The clearest losing micro-theme was semiconductor hardware. SMH fell 7.31%, materially lagging the market, even though company-level product development headlines continued. Applied Materials introduced a suite of new chipmaking systems, and separate analyst commentary lifted interest in NXP, but the broader message from the tape was that investors were reducing exposure to chip capital equipment and AI-adjacent cyclicals. Outside tech, regional banks stood out positively against the S&P 500, consistent with the week’s preference for domestic, valuation-sensitive cyclicals over expensive secular growth.

• Institutional tone favored healthcare stories with visible clinical milestones.
• Bottom-up support for semiconductor names persisted, but price action overruled it at the group level.
• Regional banks’ outperformance points to improving appetite for domestic financial exposure despite broader index weakness.
• For the coming week, the key test is whether analyst support in tech can stabilize price action or whether rotation continues toward healthcare, utilities, and real estate.

The most useful institutional read-through from the week came from analyst and strategic commentary rather than fresh filer disclosures. Commentary around semiconductors showed that stock-specific support still exists inside the group, including new equipment introductions at AMAT and a higher target on NXPI, but those positives were not enough to stop the sector’s relative unwind. That gap between supportive bottom-up research and weak price action is itself informative: the market is demanding more valuation discipline in hardware and AI-linked cyclicals.

In healthcare, the tone was more aligned: clinical and therapeutic developments supported the tape, especially in biotech and immunology-linked names. The contrast between supportive healthcare fundamentals and faltering tech leadership suggests institutions were favoring catalyst-backed defensives and selective growth over the broad secular-growth trade.

• Biotech’s outperformance looks catalyst-backed rather than purely macro-defensive.
• Phase 3 and post-hoc clinical updates are the type of news flow that can sustain interest beyond a single week.
• If healthcare broadens while semiconductors stay weak, relative leadership could become more durable.
• If biotech leadership narrows quickly, the move may prove more tactical than structural.

Biotech deserves the extra focus because it was not just the top sector but the top refined-theme standout, with XBI up 10.42% and alpha above 12 points versus the S&P 500. The fresh Johnson & Johnson update matters because it reinforced sustained disease control in a Phase 3 setting for generalized myasthenia gravis and highlighted ongoing evidence generation around nipocalimab. In a market rotating away from crowded megacap growth, that kind of catalyst can attract capital because it is differentiated, fundamentally legible, and less tied to broad index factor swings.

What to watch before the next open is whether healthcare leadership broadens from biotech into the rest of the sector or stays narrowly catalyst-driven. If biotech continues to outperform while tech remains under pressure, that would strengthen the case that the market is favoring stock-specific clinical upside and defensiveness at the same time.